Vaxcyte, Inc.: T. Rowe Price Investment Management, Inc. amends Schedule 13G stake filing
Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.
T. Rowe Price Investment Management amended its Schedule 13G filing for Vaxcyte, Inc., updating its disclosed stake in the clinical-stage vaccine developer with the SEC under accession number 0001897612-26-000705. The filing, submitted to the regulator, revises the asset manager's previously reported ownership position in the company. Vaxcyte is developing pneumococcal conjugate vaccine candidates, and its shareholder base is closely watched given the capital-intensive nature of late-stage vaccine trials. Investors will look to the amended filing for the precise share count and percentage owned, which the headline did not specify.
Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13G's report. It can get details wrong, so check the source.
Named in this story
T. Rowe Price Investment Management, Inc., Vaxcyte, Inc.